Fabio Rigat

Fabio Rigat, PhD, possesses extensive experience in biostatistics and oncology statistics, with key roles at prominent pharmaceutical companies. At The Janssen Pharmaceutical Companies of Johnson & Johnson, Fabio established the clinical statistics function in the UK and led the oncology group. Presently serving as Executive Director and GI Strategy Head in Late Oncology Statistics at AstraZeneca, Fabio oversees biometrics strategy and execution of gastrointestinal late development oncology trials. Previous positions include leading preclinical research biostatistics at Novartis and directing oncology statistics at GSK, where responsibilities encompassed modeling biomarker endpoints and advancing statistical innovation. Fabio's academic background includes a PhD from Duke University in Statistical Modeling and a BSc in Econometrics from Universita'di Pavia.